As of November 10, 2026, 4 holders' latest Schedule 13D or 13G filings report owning 5% or more of Newamsterdam Pharma Company Nv. The largest reported stake is Capital World Investors', at 10.4%. 16 filings are on record since August 12, 2025 (Schedule 13G/A, June 4, 2026).
Sell to companies like Newamsterdam Pharma Company Nv? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Fmr LLC · Sole voting: 11,931,218 · Shared voting: 0 · Sole dispositive: 11,941,763 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-11-05
- · Reporting person: Frazier Life Sciences X, L.P. · Sole voting: 0 · Shared voting: 7,329,857 · Sole dispositive: 0 · Shared dispositive: 7,329,857 · SCHEDULE 13D/A, 2026-09-22
- · Holder: Fmr LLC · Percent: 8.8% · SCHEDULE 13G/A
- · Reporting person: Capital World Investors · Sole voting: 12,188,377 · Shared voting: 0 · Sole dispositive: 12,188,377 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-06-04
- · Holder: BCLS II Investco, LP · Percent: 1.76% · SCHEDULE 13D/A
Newamsterdam Pharma Company Nv has 16 Schedule 13D or 13G filings on record since 2025-08-12. 4 holders' latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Capital World Investors | 10.4% | 12,188,377 | SCHEDULE 13G/A, 2026-06-04 | 2026-05-29 |
| Fmr LLC | 10% | 11,941,763 | SCHEDULE 13G/A, 2026-11-05 | 2026-09-30 |
| Frazier Life Sciences X, L.P. | 8.7% | 7,329,857 | SCHEDULE 13D/A, 2026-09-22 | 2026-09-18 |
| Forbion Capital Fund IV Cooperatief U.A. | 8.3% | 4,668,889 | SCHEDULE 13D/A, 2025-09-30 | 2025-09-26 |
| Viking Global Investors LP | 3.7% | 4,203,567 | SCHEDULE 13G/A, 2026-02-17 | 2025-12-31 |
| BCLS II Investco, LP | 1.76% | 114,017 | SCHEDULE 13D/A, 2026-05-14 | 2026-05-12 |
Holding shares or following this stake? See who's behind Newamsterdam Pharma Company Nv and the warning signs.
Free to see. No signup.
Keep reading
More on Newamsterdam Pharma Company Nv and the records around it.
Newamsterdam Pharma Company Nv elsewhere on the record
- Leadership changes Aug 2026
- Who owns it
Companies that share a holder
- Frazier Life Sciences X, L.P. also filed stake reports on 1 other company: Aspen Neuroscience, Inc. (Nov 2026)
- VIKING GLOBAL INVESTORS LP also filed stake reports on 27 other companies: City Therapeutics, Inc. (Oct 2026), MID AMERICA APARTMENT COMMUNITIES INC. (Oct 2026), REGAL REXNORD CORP (Sep 2026)
- Capital World Investors also filed stake reports on 125 other companies: New Fortress Energy Inc. (Oct 2026), Aura Minerals Inc. (Oct 2026), Skyworks Solutions, Inc. (Oct 2026)
Watch Newamsterdam Pharma Company Nv
Get an email when Newamsterdam Pharma Company Nv files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Newamsterdam Pharma Company Nv?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Newamsterdam Pharma Company Nv: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Newamsterdam Pharma Company Nv covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
20 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Capital World Investors | 12,188,377 | 0 | 12,188,377 | 0 | SCHEDULE 13G/A, 2026-06-04 |
| Fmr LLC | 11,931,218 | 0 | 11,941,763 | 0 | SCHEDULE 13G/A, 2026-11-05 |
| Abigail P. Johnson | 0 | 0 | 11,941,763 | 0 | SCHEDULE 13G/A, 2026-11-05 |
| Frazier Life Sciences X, L.P. | 0 | 7,329,857 | 0 | 7,329,857 | SCHEDULE 13D/A, 2026-09-22 |
| Frazier Lifesciences Sponsor LLC | 0 | 3,968,000 | 0 | 3,968,000 | SCHEDULE 13D/A, 2026-09-22 |
| Fhmls X, L.P. | 0 | 7,329,857 | 0 | 7,329,857 | SCHEDULE 13D/A, 2026-09-22 |
| Fhmls X, L.L.C. | 0 | 7,329,857 | 0 | 7,329,857 | SCHEDULE 13D/A, 2026-09-22 |
| Frazier Life Sciences Public Fund, L.P. | 0 | 10,424,224 | 0 | 10,424,224 | SCHEDULE 13D/A, 2026-09-22 |
| Fhmlsp, L.P. | 0 | 10,424,224 | 0 | 10,424,224 | SCHEDULE 13D/A, 2026-09-22 |
| Fhmlsp, L.L.C. | 0 | 10,424,224 | 0 | 10,424,224 | SCHEDULE 13D/A, 2026-09-22 |
| Frazier Life Sciences XI, L.P. | 0 | 1,319,923 | 0 | 1,319,923 | SCHEDULE 13D/A, 2026-09-22 |
| Fhmls Xi, L.P. | 0 | 1,319,923 | 0 | 1,319,923 | SCHEDULE 13D/A, 2026-09-22 |
| Fhmls Xi, L.L.C. | 0 | 1,319,923 | 0 | 1,319,923 | SCHEDULE 13D/A, 2026-09-22 |
| Frazier Life Sciences XII, L.P. | 0 | 365,231 | 0 | 365,231 | SCHEDULE 13D/A, 2026-09-22 |
| Fhmls Xii, L.P. | 0 | 365,231 | 0 | 365,231 | SCHEDULE 13D/A, 2026-09-22 |
| Fhmls Xii, L.L.C. | 0 | 365,231 | 0 | 365,231 | SCHEDULE 13D/A, 2026-09-22 |
| James N. Topper | 0 | 7,329,857 | 0 | 7,329,857 | SCHEDULE 13D/A, 2026-09-22 |
| Patrick J. Heron | 0 | 7,329,857 | 0 | 7,329,857 | SCHEDULE 13D/A, 2026-09-22 |
The latest filing identifies Newamsterdam Pharma Company Nv by CUSIP N62509109 and gives its principal executive office as GOOIMEER 2-35, NARRDEN (SCHEDULE 13G/A, 2026-11-05).
Source of funds (Item 3)
Item 3 of the Schedule 13D is hereby amended to incorporate Item 5(c) hereof.Frazier Life Sciences X, L.P., SCHEDULE 13D/A, 2026-09-22
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-08-12 | Forbion Capital Fund IV Cooperatief U.A. | 9.4% | SCHEDULE 13D/A |
| 2025-08-13 | Capital World Investors | 7.5% | SCHEDULE 13G/A |
| 2025-08-20 | Frazier Life Sciences X, L.P. | 6.5% | SCHEDULE 13D/A |
| 2025-09-30 | Forbion Capital Fund IV Cooperatief U.A. | 8.3% | SCHEDULE 13D/A |
| 2025-11-04 | Frazier Life Sciences X, L.P. | 7.7% | SCHEDULE 13D/A |
| 2025-11-07 | BCLS II Investco, LP | 9.99% | SCHEDULE 13D/A |
| 2025-11-13 | Capital World Investors | 8.7% | SCHEDULE 13G/A |
| 2025-12-04 | BCLS II Investco, LP | 4.7% | SCHEDULE 13D/A |
| 2026-02-05 | Fmr LLC | 5.7% | SCHEDULE 13G |
| 2026-02-17 | Viking Global Investors LP | 3.7% | SCHEDULE 13G/A |
| 2026-05-06 | Fmr LLC | 7.6% | SCHEDULE 13G/A |
| 2026-05-14 | BCLS II Investco, LP | 1.76% | SCHEDULE 13D/A |
| 2026-06-04 | Capital World Investors | 10.4% | SCHEDULE 13G/A |
| 2026-08-06 | Fmr LLC | 8.8% | SCHEDULE 13G/A |
| 2026-09-22 | Frazier Life Sciences X, L.P. | 8.7% | SCHEDULE 13D/A |
| 2026-11-05 | Fmr LLC | 10% | SCHEDULE 13G/A |
Questions about who owns Newamsterdam Pharma Company Nv
Who owns Newamsterdam Pharma Company Nv?
On this page, 4 holders' latest ownership filings report 5% or more of Newamsterdam Pharma Company Nv: Capital World Investors (10.4%, Schedule 13G/A, filed 2026-06-04), Fmr LLC (10%, Schedule 13G/A, filed 2026-11-05), Frazier Life Sciences X, L.P. (8.7%, Schedule 13D/A, filed 2026-09-22) and Forbion Capital Fund IV Cooperatief U.A. (8.3%, Schedule 13D/A, filed 2025-09-30).
Who are the largest shareholders of Newamsterdam Pharma Company Nv?
By the share each holder's latest filing reports, the largest holders of Newamsterdam Pharma Company Nv on this page are Capital World Investors (10.4%), Fmr LLC (10%) and Frazier Life Sciences X, L.P. (8.7%).
When did Capital World Investors buy into Newamsterdam Pharma Company Nv?
The filings give report dates, not purchase dates. The earliest filing from Capital World Investors on this page is the Schedule 13G/A, filed 2025-08-13, reporting 7.5%; its latest, Schedule 13G/A filed 2026-06-04, reports 10.4%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 16 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Also on the record for Newamsterdam Pharma Company Nv
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| August 14, 2026 | Leadership change filing (Form 8-K, Item 5.02) | — | Leadership changes | Source |
| August 14, 2026 | Leadership change: Robert W. Gunning appointed | — | Leadership changes | Source |
| July 22, 2026 | Leadership change filing (Form 8-K, Item 5.02) | — | Leadership changes | Source |
| April 24, 2026 | Leadership change filing (Form 8-K, Item 5.02) | — | Leadership changes | Source |
Tools for this story
Each opens in a new tab, filled in for Newamsterdam Pharma Company Nv. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.